Indications for fetal echocardiography:
At 11-14 weeks
- Nuchal translucency ≥ 3.5 mm
- Suspected cardiac abnormality during ultrasound examination
- Previous history of a child / children with severe cardiac damage (eg large vessel translocation, hypoplastic left heart syndrome)
- All women at risk ≥ 1: 300 (at 12 weeks) without further prenatal control (eg CVS)
At 20-24 weeks
- Suspected cardiac abnormality during ultrasound examination
- Increased nuchal translucency (over 95th position) or tricuspid valve reflux at 11-13 weeks
- Reverse flow into the ductus venosus at 11-13 weeks
- Fetal hydrops
- Monochorionic twin pregnancies
- Family history (mother, father, child / fetus) with congenital heart disease
- Genetic anomaly history
- Congenital infections
- Exposure to known teratogenic substances during pregnancy
- Insulin-dependent diabetic mother
- Epileptic mother in anti-epileptic treatment
- Anti-Ro, anti-La antibodies (collagen diseases)
Early diagnosis and detection of pregnant women with high risk for congenital heart disease is an important advance in the field of prenatal diagnosis.
Congenital heart disease is present at about 8-9 among 1,000 births. It is still one of the most serious abnormalities in the fetus and therefore their prenatal identification makes it possible to have better counseling for the couple and significantly improves the perinatal outcome.